Disease · MONDO_0004652
bacterial pneumonia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bacterial pneumonia. Diseases, record MONDO_0004652. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004652
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Bacteria caused pneumonia, Bacteria pneumonia, Pneumonia, Bacterial, pneumonia due to other gram-negative bacteria
- Open Targets
- Highest stage of its drugs
- Approval, for 13 of its 27 drugs, from DailyMed, EMA Human Drugs, FDA and TTD
- Open Targets
Drugs27
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| OMADACYCLINE | CHEMBL1689772 | Small molecule | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| LEFAMULIN ACETATE | CHEMBL3545309 | Small molecule | Approval | FDA | 2 | 0 | 0 | Drugs and targets |
| TELAVANCIN HYDROCHLORIDE | CHEMBL3301680 | Protein | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| AVIBACTAM | CHEMBL1689063 | Small molecule | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| CEFIDEROCOL SULFATE TOSYLATE | CHEMBL4297211 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| CEFTAROLINE FOSAMIL ACETATE | CHEMBL3544973 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| CEFTAZIDIME | CHEMBL44354 | Small molecule | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| DORIPENEM | CHEMBL491571 | Small molecule | Approval | EMA Human Drugs, at withdrawal | 1 | 0 | 0 | Drugs and targets |
| ERTAPENEM | CHEMBL1359 | Small molecule | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| LEFAMULIN | CHEMBL3291398 | Small molecule | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 27
See all 27 drugsTargets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01371838 | A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia | Phase 3 | 848 | 2014-09-23 | Community-Acquired Bacterial Pneumonia, Lung Infection of Individual Not Recently Hospitalized | CEFTAROLINE FOSAMIL, CEFTRIAXONE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03583333 | Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016) | Phase 3 | 274 | 2023-06-28 | Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia | IMIPENEM, RELEBACTAM | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03894046 | Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex | Phase 3 | 207 | 2023-02-01 | Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC | DURLOBACTAM, SULBACTAM | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02605122 | Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia | Phase 2/3 | 97 | 2019-01-03 | Community-acquired Bacterial Pneumonia | SOLITHROMYCIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03862040 | Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia | Phase 1 | 7 | 2020-11-05 | Bacterial Pneumonia | CEFIDEROCOL | Its record names the disease | ClinicalTrials.gov |
| NCT01968733 | Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia | Phase 3 | 863 | Community-acquired Bacterial Pneumonia | MOXIFLOXACIN, SOLITHROMYCIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT01756339 | Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia | Phase 3 | 860 | Community-acquired Bacterial Pneumonia | MOXIFLOXACIN, SOLITHROMYCIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT01168713 | Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia | Phase 2 | 132 | Community-Acquired Bacterial Pneumonia | LEVOFLOXACIN, SOLITHROMYCIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT06162286 | A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP | Phase 3 | 100 | Community-acquired Bacterial Pneumonia | OMADACYCLINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01561794 | A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia | Phase 3 | 44 | Pneumonia | CIPROFLOXACIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ceftaroline 600mg vs Ceftriaxone 2g: serious adverse events | 30 of 381 | 29 of 383 | 764 | NCT01371838 | Trial comparisons |
| IMI/REL vs PIP/TAZ: deaths from any cause | 18 of 138 | 11 of 136 | 274 | NCT03583333 | Trial comparisons |
| IMI/REL vs PIP/TAZ: serious adverse events | 29 of 134 | 21 of 136 | 270 | NCT03583333 | Trial comparisons |
| Part A - Group 1 vs Part A - Group 2: Proportion of Patients With Nephrotoxicity | 12 of 91 | 32 of 85 | 176 | NCT03894046 | Trial comparisons |
| Part A - Group 1 vs Part A - Group 2: Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population | 12 of 63 | 20 of 62 | 125 | NCT03894046 | Trial comparisons |
| Solithromycin vs Standard of Care: deaths from any cause | 0 of 70 | 0 of 24 | 94 | NCT02605122 | Trial comparisons |
| Solithromycin vs Standard of Care: serious adverse events | 1 of 70 | 1 of 24 | 94 | NCT02605122 | Trial comparisons |
Papers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 39674398 | RESULT | 1 | PubMed |
| 37182534 | DERIVED | 1 | PubMed |
| 35237053 | DERIVED | 1 | PubMed |
| 34922058 | DERIVED | 1 | PubMed |
| 31044546 | DERIVED | 1 | PubMed |
| 30597021 | DERIVED | 1 | PubMed |
| 30380060 | DERIVED | 1 | PubMed |
| 27448679 | DERIVED | 1 | PubMed |
| 26852726 | DERIVED | 1 | PubMed |
| 26702925 | DERIVED | 1 | PubMed |
1 to 10 of 12
See all 12 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004652
GET https://conductscience.org/api/diseases/v1/MONDO_0004652/drugs?page=2